Impaired Toll-like receptor 7 and 9 signaling: From chronic viral infections to cancer

Trends in Immunology

Volumn 31, Issue 10, 2010, Pages 391-397

  Hirsch, Ivan ^a   Caux, Christophe ^b   Hasan, Uzma ^c   Bendriss Vermare, Nathalie ^b   Olive, Daniel ^a  

^a INSERM   (France)

^b CENTRE LÉON BÉRARD   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; IMIQUIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN KINASE SYK; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

BREAST CARCINOMA; CARCINOGENESIS; CONDYLOMA ACUMINATUM; DOWN REGULATION; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HEPATITIS C; HUMAN; INNATE IMMUNITY; INTERFERON PRODUCTION; KERATINOCYTE; MELANOMA; NONHUMAN; OVARY CARCINOMA; PLASMACYTOID DENDRITIC CELL; REVIEW; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; VIRUS INFECTION; VIRUS PARTICLE;

EID: 77957263266     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2010.07.004     Document Type: Review

References (81)

1. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11:373-384.
2. Gilliet M., et al. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 2008, 8:594-606.
3. Diacovo T.G., et al. Adhesive mechanisms governing interferon-producing cell recruitment into lymph nodes. J. Exp. Med. 2005, 202:687-696.
4. Vermi W., et al. Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inflamed skin. J. Exp. Med. 2005, 201:509-515.
5. Martinelli E., et al. HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:3396-3401.
6. Nascimbeni M., et al. Plasmacytoid dendritic cells accumulate in spleens from chronically HIV-infected patients but barely participate in interferon-alpha expression. Blood 2009, 113:6112-6119.
7. Xie Q., et al. Patients with chronic hepatitis B infection display deficiency of plasmacytoid dendritic cells with reduced expression of TLR9. Microbes. Infect. 2009, 11:515-523.
8. Xu Y., et al. HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. Mol. Immunol. 2009, 46:2640-2646.
9. Shiina M., Rehermann B. Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. Hepatology 2008, 47:385-395.
10. Gondois-Rey F., et al. Hepatitis C virus is a weak inducer of interferon alpha in plasmacytoid dendritic cells in comparison with influenza and human herpesvirus type-1. PLoS ONE 2009, 4:e4319.
11. Hasan U.A., et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J. Immunol. 2007, 178:3186-3197.
12. Hartmann E., et al. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res. 2003, 63:6478-6487.
13. Cai D., et al. Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis. BMC Cancer 2009, 9:102.
14. Cao W., et al. Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J. Exp. Med. 2009, 206:1603-1614.
15. Sisirak, V., et al. (2008) Breast tumor environment inhibits human plasmacytoid dendritic cells functions. In The 10th International Symposium on Dendritic Cells (Kobe, Japan). pp. P-4-03.
16. Lambert A.A., et al. The C-type lectin surface receptor DCIR acts as a new attachment factor for HIV-1 in dendritic cells and contributes to trans- and cis-infection pathways. Blood 2008, 112:1299-1307.
17. Cao W., et al. BDCA2/Fc epsilon RI gamma complex signals through a novel BCR-like pathway in human plasmacytoid dendritic cells. PLoS Biol 2007, 5:e248.
18. Meyer-Wentrup F., et al. Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production. Blood 2008, 111:4245-4253.
19. Tsukamoto N., et al. Impairment of plasmacytoid dendritic cells for IFN production by the ligand for immunoglobulin-like transcript 7 expressed on human cancer cells. Clin. Cancer Res. 2009, 15:5733-5743.
20. Kim Y.M., et al. UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. Nature 2008, 452:234-238.
21. Yoshizaki M., et al. Spatiotemporal regulation of intracellular trafficking of Toll-like receptor 9 by an inhibitory receptor, Ly49Q. Blood 2009, 114:1518-1527.
22. Ewald S.E., et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 2008, 456:658-662.
23. Sepulveda F.E., et al. Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells. Immunity 2009, 31:737-748.
24. Honda K., et al. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 2005, 434:1035-1040.
25. Blanco P., et al. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001, 294:1540-1543.
26. Dzionek A., et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J. Exp. Med. 2001, 194:1823-1834.
27. Cao W., et al. Plasmacytoid dendritic cell-specific receptor ILT7-Fc epsilonRI gamma inhibits Toll-like receptor-induced interferon production. J. Exp. Med. 2006, 203:1399-1405.
28. Green D.S., et al. IgG-derived Fc down-regulates virus-induced plasmacytoid dendritic cell (pDC) IFNalpha production. Cytokine 2004, 26:209-216.
29. Schroeder J.T., et al. Toll-like receptor 9 suppression in plasmacytoid dendritic cells after IgE-dependent activation is mediated by autocrine TNF-alpha. J. Allergy Clin. Immunol. 2008, 121:486-491.
30. Fuchs A., et al. Paradoxic inhibition of human natural interferon-producing cells by the activating receptor NKp44. Blood 2005, 106:2076-2082.
31. Hamerman J.A., Lanier L.L. Inhibition of immune responses by ITAM-bearing receptors. Sci STKE 2006, 2006:re1.
32. Blasius A.L., et al. Siglec-H is an IPC-specific receptor that modulates type I IFN secretion through DAP12. Blood 2006, 107:2474-2476.
33. Barrow A.D., Trowsdale J. You say ITAM and I say ITIM, let's call the whole thing off: the ambiguity of immunoreceptor signalling. Eur. J. Immunol. 2006, 36:1646-1653.
34. Swiecki M., Colonna M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol. Rev. 2010, 234:142-162.
35. Zou W., et al. DAP12 couples c-Fms activation to the osteoclast cytoskeleton by recruitment of Syk. Mol. Cell 2008, 31:422-431.
36. Takeshita F., et al. Transcriptional regulation of the human TLR9 gene. J. Immunol. 2004, 173:2552-2561.
37. Marshall J.D., et al. Negative regulation of TLR9-mediated IFN-alpha induction by a small-molecule, synthetic TLR7 ligand. J. Leukoc. Biol. 2007, 82:497-508.
38. Fukui R., et al. Unc93B1 biases Toll-like receptor responses to nucleic acid in dendritic cells toward DNA- but against RNA-sensing. J. Exp. Med. 2009, 206:1339-1350.
39. Ito T., et al. Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells. Blood 2006, 107:2423-2431.
40. Christensen S.R., et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006, 25:417-428.
41. Conry S.J., et al. Impaired plasmacytoid dendritic cell (PDC)-NK cell activity in viremic human immunodeficiency virus infection attributable to impairments in both PDC and NK function. J. Virol. 2009, 83:11175-11187.
42. Dolganiuc A., et al. Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. J. Immunol. 2006, 177:6758-6768.
43. Ulsenheimer A., et al. Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection. Hepatology 2005, 41:643-651.
44. Decalf J., et al. Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients. J. Exp. Med. 2007, 204:2423-2437.
45. Beignon A.S., et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J. Clin. Invest. 2005, 115:3265-3275.
46. Zhang Y.L., et al. Hepatitis C virus single-stranded RNA induces innate immunity via Toll-like receptor 7. J. Hepatol. 2009, 51:29-38.
47. Takahashi K., et al. Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:7431-7436.
48. Abe T., et al. Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines. J. Virol. 2007, 81:8953-8966.
49. Amjad M., et al. Decreased interferon-alpha production and impaired regulatory function of plasmacytoid dendritic cells induced by the hepatitis C virus NS 5 protein. Microbiol. Immunol. 2008, 52:499-507.
50. Munoz N., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 2003, 348:518-527.
51. Melief C.J. Cancer immunotherapy by dendritic cells. Immunity 2008, 29:372-383.
52. Vulink A., et al. Dendritic cells in cancer immunotherapy. Adv. Cancer Res. 2008, 99:363-407.
53. Gerlini G., et al. Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. Clin. Immunol. 2007, 125:184-193.
54. Kawai S., et al. Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models. Cancer Sci. 2008, 99:2461-2466.
55. Wang W., et al. HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody. Cancer Immunol. Immunother. 2009, 58:967-976.
56. Labidi-Galy, S.I., et al. (2010) Infiltration of ovarian carcinoma by altered plasmacytoid dendritic cells could contribute to local immune tolerance. In The 101st Annual Meeting of the American Association for Cancer Research (AACR, Washington, DC). Session PO.IM01.01. Abstract 1910.
57. Perrot I., et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J. Immunol. 2007, 178:2763-2769.
58. Son Y., et al. Prostaglandin E2 is a negative regulator on human plasmacytoid dendritic cells. Immunology 2006, 119:36-42.
59. Contractor N., et al. Cutting edge: Peyer's patch plasmacytoid dendritic cells (pDCs) produce low levels of type I interferons: possible role for IL-10, TGFbeta, and prostaglandin E2 in conditioning a unique mucosal pDC phenotype. J. Immunol. 2007, 179:2690-2694.
60. Li L., et al. Splenic stromal microenvironment negatively regulates virus-activated plasmacytoid dendritic cells through TGF-beta. J. Immunol. 2008, 180:2951-2956.
61. Bekeredjian-Ding I., et al. Tumour-derived prostaglandin E and transforming growth factor-beta synergize to inhibit plasmacytoid dendritic cell-derived interferon-alpha. Immunology 2009, 128:439-450.
62. Dunn G.P., et al. A critical function for type I interferons in cancer immunoediting. Nat. Immunol. 2005, 6:722-729.
63. Picaud S., et al. Enhanced tumor development in mice lacking a functional type I interferon receptor. J. Interferon Cytokine Res. 2002, 22:457-462.
64. Brassard D.L., et al. Interferon-alpha as an immunotherapeutic protein. J. Leukoc. Biol. 2002, 71:565-581.
65. Takaoka A., et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003, 424:516-523.
66. Thyrell L., et al. Mechanisms of interferon-alpha induced apoptosis in malignant cells. Oncogene 2002, 21:1251-1262.
67. Wenzel J., et al. Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions. Am. J. Clin. Pathol. 2005, 124:37-48.
68. Domschke C., et al. Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res. 2009, 69:8420-8428.
69. Urosevic M., et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J. Natl. Cancer Inst. 2005, 97:1143-1153.
70. Urosevic M., et al. Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas. J. Clin. Invest. 2007, 117:2834-2846.
71. Stary G., et al. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J. Exp. Med. 2007, 204:1441-1451.
72. Palamara F., et al. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J. Immunol. 2004, 173:3051-3061.
73. Krieg A.M. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008, 27:161-167.
74. Pockros P.J., et al. Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J. Hepatol. 2007, 47:174-182.
75. Horsmans Y., et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 2005, 42:724-731.
76. Vicari A.P., et al. Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILOM), an investigational synthetic toll-like receptor 9 agonist. Antivir. Ther. 2007, 12:741-751.
77. McHutchison J.G., et al. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 2007, 46:1341-1349.
78. Tyring S.K., et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J. Infect. Dis. 1998, 178:551-555.
79. Arany I., et al. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res. 1999, 43:55-63.
80. Perez-Caballero D., et al. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 2009, 139:499-511.
81. Tokarev A., et al. Antiviral activity of the interferon-induced cellular protein BST-2/tetherin. AIDS Res. Hum. Retroviruses 2009, 25:1197-1210.